JAMA Neurology SEPTEMBER 01, 2018

Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial

Virginia L. Stauffer, David W. Dodick, Q. Zhang, et al.

Bottom Line

The EVOLVE-1 trial demonstrated that monthly subcutaneous injections of galcanezumab (120 mg or 240 mg) significantly reduced monthly migraine headache days compared to placebo in patients with episodic migraine.

Key Findings

1. Patients receiving 120 mg of galcanezumab experienced a reduction of 4.7 monthly migraine headache days (MHDs), and those receiving 240 mg experienced a reduction of 4.6 MHDs, compared to 2.8 MHDs in the placebo group (P < .001 for both comparisons).

2. A significantly higher proportion of patients treated with galcanezumab achieved a ≥50% reduction in monthly MHDs (62.3% for 120 mg and 60.9% for 240 mg) compared to 38.6% in the placebo group (P < .001).

3. Secondary endpoints, including ≥75% and 100% reduction in MHDs and improvements in quality of life (Migraine-Specific Quality of Life questionnaire scores), were significantly superior in both galcanezumab arms compared to placebo.

4. The discontinuation rate due to adverse events was low, at less than 5% across all study groups, indicating a favorable tolerability profile.

Study Design

Design

RCT

Double-Blind

Sample

858

Patients

Duration

5 mo

Median

Setting

Multicenter, North America

Population Adults aged 18 to 65 with a ≥1-year history of episodic migraine, 4–14 migraine headache days per month, and migraine onset prior to age 50.

Intervention Subcutaneous injection of galcanezumab 120 mg or 240 mg once monthly for 6 months.

Comparator Subcutaneous placebo injection once monthly for 6 months.

Outcome Overall mean change from baseline in the number of monthly migraine headache days during the 6-month treatment period.

Study Limitations

• The study was restricted to a 6-month treatment period, limiting conclusions regarding the long-term safety and sustained efficacy of the medication beyond this duration.

• The population was limited to adults aged 18 to 65 with a migraine onset prior to age 50, potentially limiting the generalizability of the findings to older patients or those with different migraine profiles.

• The trial excluded patients with chronic migraine, and the results do not necessarily extrapolate to those with more frequent or refractory forms of the disease.

Clinical Significance

The results of the EVOLVE-1 trial provided critical phase 3 evidence supporting the efficacy of galcanezumab as a CGRP-targeting monoclonal antibody for migraine prophylaxis, offering a targeted alternative to traditional oral preventive medications with a favorable safety and tolerability profile.

Historical Context

The EVOLVE-1 trial was a pivotal study in the emerging class of calcitonin gene-related peptide (CGRP) inhibitors, which transformed migraine management by introducing monoclonal antibodies designed specifically to target the CGRP pathway, a key driver of migraine pathophysiology.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Galcanezumab is a humanized monoclonal antibody used for migraine prevention. What is its specific molecular target, and how does this mechanism differ from the 'gepant' class of medications?

Key Response

Galcanezumab binds specifically to the Calcitonin Gene-Related Peptide (CGRP) ligand itself, preventing it from binding to its receptor. In contrast, 'gepants' (like ubrogepant or rimegepant) are small-molecule antagonists that compete for the CGRP receptor site. Understanding this distinction is foundational for grasping the pharmacology of CGRP-pathway inhibition.

Resident

In the EVOLVE-1 trial, galcanezumab demonstrated a significant reduction in monthly migraine days (MMD). Based on the study's safety and efficacy profile, how does the 'time-to-onset' for galcanezumab compare to traditional oral preventatives like topiramate or propranolol?

Key Response

Galcanezumab shows a rapid onset of effect, often within the first month (and sometimes within the first week), whereas traditional oral preventatives typically require 2-3 months for dose titration and therapeutic effect. This makes it a high-yield clinical point for patient counseling regarding expectations for relief.

Fellow

The EVOLVE-1 trial evaluated both 120 mg and 240 mg doses of galcanezumab. Given that both doses showed nearly identical efficacy in reducing MMDs, what pharmacological or clinical factors might justify the use of a 240 mg loading dose followed by 120 mg monthly, rather than simply starting at 120 mg?

Key Response

The 240 mg loading dose is used to reach steady-state therapeutic concentrations more rapidly due to the long half-life of monoclonal antibodies (approx. 27 days). While the higher 240 mg maintenance dose didn't provide superior efficacy in this episodic population, the loading dose strategy ensures the 'receptor saturation' threshold is met earlier in the treatment course.

Attending

EVOLVE-1 excluded patients who had previously failed three or more classes of migraine preventatives due to lack of efficacy. How does this 'clean' population design impact the generalizability of the results to a tertiary headache clinic, and how should we interpret the NNT (Number Needed to Treat) in more refractory patients?

Key Response

The exclusion of refractory patients (who have failed 3+ classes) likely inflates the perceived efficacy compared to real-world 'difficult-to-treat' populations. In clinical practice, we often see patients who failed multiple preventatives; subsequent trials (like CONQUER) specifically addressed this, showing that while CGRP mAbs still work, the magnitude of benefit and NNT may be less favorable than in the treatment-naive EVOLVE-1 cohort.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The primary endpoint in EVOLVE-1 was analyzed using a Mixed Model for Repeated Measures (MMRM). Critique the choice of this statistical model over a 'Last Observation Carried Forward' (LOCF) approach, specifically regarding the handling of missing data in a 6-month longitudinal trial.

Key Response

MMRM is superior to LOCF because it uses all available data and provides unbiased estimates of treatment effects under the 'Missing at Random' (MAR) assumption. LOCF can artificially reduce variance and introduce bias if patients drop out due to lack of efficacy or side effects, which is common in migraine trials. MMRM better accounts for the correlation of measurements within the same patient over time.

Journal Editor

The placebo group in EVOLVE-1 experienced a reduction of nearly 2 monthly migraine days. What aspects of the trial's delivery method and study design might contribute to this high placebo response, and does the 2-day delta over placebo meet the threshold for 'clinically meaningful' versus 'statistically significant' improvement?

Key Response

Injectable therapies often elicit a higher placebo response than oral pills (the 'placebo-by-procedure' effect). A tough reviewer would flag that while a ~2 day difference over placebo is statistically significant (p < 0.001), the absolute gain is modest. However, secondary endpoints like '50% responder rate' are often used by editors to argue for clinical meaningfulness, as a 50% reduction in burden is a transformative outcome for many patients.

Guideline Committee

Current AHS/AAN guidelines typically suggest a trial of two or more 'level A' oral preventatives before transitioning to CGRP monoclonal antibodies. Does the evidence from EVOLVE-1 regarding the side-effect profile and safety (e.g., lack of CNS side effects) justify moving galcanezumab to a first-line recommendation despite its higher cost?

Key Response

EVOLVE-1 highlights a superior tolerability profile compared to traditional preventatives (which often cause weight gain, cognitive slowing, or fatigue). While the evidence level for efficacy is 'Level A', guideline committees must balance this against cost-effectiveness. Currently, the high cost prevents first-line status, but the 'strength of recommendation' for CGRP mAbs is increasingly supported by their high retention rates and lower side-effect burden compared to historical standards.

Clinical Landscape

Noteworthy Related Trials

2017

EVOLVE-2 Trial

n = 915 · Lancet Neurol

Tested

Galcanezumab 120 mg or 240 mg

Population

Patients with episodic migraine

Comparator

Placebo

Endpoint

Mean change from baseline in monthly migraine headache days

Key result: Galcanezumab significantly reduced the number of monthly migraine days compared to placebo over 6 months.

2017

HALO-EM Trial

n = 875 · JAMA

Tested

Fremanezumab quarterly or monthly

Population

Patients with episodic migraine

Comparator

Placebo

Endpoint

Mean change from baseline in monthly migraine days

Key result: Both monthly and quarterly dosing of fremanezumab demonstrated a significant reduction in monthly migraine days compared to placebo.

2017

STRIVE Trial

n = 955 · NEJM

Tested

Erenumab 70 mg or 140 mg

Population

Patients with episodic migraine

Comparator

Placebo

Endpoint

Change from baseline in monthly migraine days

Key result: Erenumab, a CGRP receptor antagonist, significantly reduced monthly migraine days over a 6-month period.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis